Pathologic diagnosis of lung cancer - recent developments.

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Diagnostics

Background:

• Lung cancer diagnosis predominantly occurs at advanced stages (IV), shifting focus from resection specimens to small biopsies and cytology.
• The advent of targeted therapy necessitates molecular subtyping for effective treatment selection in lung cancer.
• Accurate pathological diagnosis is critical, especially when dealing with limited tissue from biopsies or aspirations.

Approach:

• Molecular analysis is essential for lung adenocarcinomas and specific rare carcinoma types.
• Investigating squamous cell carcinomas and adenosquamous carcinomas in never/former smokers for targetable oncogenes is recommended.
• Subtyping high-grade neuroendocrine carcinomas using immunohistochemistry (ASCL1, NeuroD1, POU2F3) is vital for potential new treatment options.

Key Points:

• Molecular subtyping is critical for lung adenocarcinomas and certain rare lung cancers.
• Immunohistochemistry aids in subtyping neuroendocrine carcinomas, potentially guiding novel therapeutic strategies.
• Molecular investigation of carcinoids can identify cases with increased risk of recurrence and metastasis.

Conclusions:

• Modern lung cancer diagnosis frequently utilizes small biopsies and cytology, reserving tissue for molecular testing.
• Molecular analysis is indispensable for adenocarcinomas and other less common lung tumor types.
• Accurate molecular classification supports personalized medicine approaches in lung cancer treatment.